Unknown

Dataset Information

Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.


ABSTRACT:

Importance

In the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, the anti-inflammatory monoclonal antibody canakinumab significantly reduced the risk of recurrent cardiovascular events in patients with previous myocardial infarction (MI) and high-sensitivity C-reactive protein (hs-CRP) levels of 2 mg/L or greater.

Objective

To estimate the cost-effectiveness of adding canakinumab to standard of care for the secondary prevention of major cardiovascular events over a range of potential prices.

Design, setting, and participants

A state-transition Markov model was constructed to estimate costs and outcomes over a lifetime horizon by projecting rates of recurrent MI, coronary revascularization, infection, and lung cancer with and without canakinumab

SUBMITTER: Sehested TSG 

PROVIDER: S-EPMC6439626 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature